Tapentadol Hydrochloride Patent Expiration
Tapentadol Hydrochloride is Used for managing severe chronic pain, including neuropathic pain associated with diabetic peripheral neuropathy, when other treatment options are inadequate. It was first introduced by Collegium Pharmaceutical Inc
Tapentadol Hydrochloride Patents
Given below is the list of patents protecting Tapentadol Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Nucynta Er |
US8536130 (Pediatric) | Use of 1 phenyl-3-dimethylamino-propane compounds for treating neuropathic pain | Mar 22, 2029 | Collegium Pharm Inc |
| Nucynta Er |
US11344512 (Pediatric) | Titration of tapentadol | Oct 21, 2028 | Collegium Pharm Inc |
| Nucynta Er | US8536130 | Use of 1 phenyl-3-dimethylamino-propane compounds for treating neuropathic pain | Sep 22, 2028 | Collegium Pharm Inc |
| Nucynta Er | US11344512 | Titration of tapentadol | Apr 21, 2028 | Collegium Pharm Inc |
| Nucynta |
US7994364 (Pediatric) | Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride | Dec 27, 2025 | Collegium Pharm Inc |
| Nucynta Er |
US7994364 (Pediatric) | Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride | Dec 27, 2025 | Collegium Pharm Inc |
| Nucynta | US7994364 | Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride | Jun 27, 2025 | Collegium Pharm Inc |
| Nucynta Er | US7994364 | Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride | Jun 27, 2025 | Collegium Pharm Inc |
| Nucynta Er | US8114383 | Abuse-proofed dosage form |
Oct 10, 2024
(Expired) | Collegium Pharm Inc |
| Nucynta Er | US8075872 | Abuse-proofed dosage form |
Nov 20, 2023
(Expired) | Collegium Pharm Inc |
| Nucynta Er | US8309060 | Abuse-proofed dosage form |
Nov 20, 2023
(Expired) | Collegium Pharm Inc |
| Nucynta Er | US8420056 | Abuse-proofed dosage form |
Nov 20, 2023
(Expired) | Collegium Pharm Inc |
| Nucynta Er | US11007156 | Prolonged release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol |
Oct 22, 2022
(Expired) | Collegium Pharm Inc |
| Nucynta | USRE39593 | 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects |
Aug 05, 2022
(Expired) | Collegium Pharm Inc |
| Nucynta Er | USRE39593 | 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects |
Aug 05, 2022
(Expired) | Collegium Pharm Inc |
| Nucynta | US6071970 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
Jun 06, 2017
(Expired) | Collegium Pharm Inc |
| Nucynta Er | US6071970 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
Jun 06, 2017
(Expired) | Collegium Pharm Inc |
Tapentadol Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List